Market research
OPK Opko Health Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 4.375
- Dividend yield
- Not available
- Beta
- 1.49
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US68375N1037
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 4.375
- Dividend yield
- Not available
- Beta
- 1.49
About
About Opko Health Inc
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OPK discussion.
5 years, 4 months ago
OPKO Health, Inc is currently in a long term downtrend where the price is trading 9.1% below its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.0.
OPKO Health, Inc's total revenue rose by 120.5% to $495M since the same quarter in the previous year.
Its net income has increased by 128.7% to $32M since the same quarter in the previous year.
Finally, its free cash flow grew by 155.0% to $27M since the same quarter in the previous year.
Based on the above factors, OPKO Health, Inc gets an overall score of 4/5.